Methods Projects

The current available real-world evidence on the potential association between GLP-1 receptor agonists and the risk of suicidality and self-harm is limited, as the studies had contradictory findings and important methodological limitations.

The purpose of this study is to describe the use of nirmaltrelvir-ritonavir and remdesivir in the outpatient setting across Canadian provinces for which data are readily available, and describe the characteristics of patients receiving these therapies. This project is a collaboration with ADTEC and INESSS.

The objective of this pilot project is to determine the utilization of antidiabetic drugs among pregnant people living in Canada using CNODES' adaptation of the Sentinel Common Data Model.

There is limited evidence on the safety of tofacitinib in patients with ulcerative colitis. The objective of this study is to describe the use of tofacitinib and other therapies among individuals diagnosed with ulcerative colitis and determine the feasibility of a comparative safety study of MACE, hospitalized thrombotic events, and cancer.

The risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with COVID-19 varied by country. This variation was observed among patients initially diagnosed in the ambulatory setting and the hospital setting, and before and during COVID-19 vaccine availability. Differences in healthcare systems, data sources, prevalence of underlying comorbid conditions, and approaches to COVID-19 and thromboembolism case definition may have contributed to the variation in thromboembolism risk estimates observed between countries.

In September 2019, Health Canada directed domestic manufacturers to cease distributing ranitidine due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). This study will characterize the use of dispensed histamine-2 receptor antagonists (H2RAs) in Canada by describing demographic and clinical characteristics of users and prescribers.